In recent days, the news of "new crown medicine" stephanine has triggered a heated debate. At the same time, it has also set off a wave of speculation in the domestic stock market. As a result, the stock prices of many companies have soared and even continued to rise by the limit. According to the economic information daily, on May 16, due to the popularity of the market caused by the concept of stephanine, biological Valley Rose 29.97% in a single day, and several stocks such as North China pharmaceutical, Fangsheng pharmaceutical, step pharmaceutical and Qianjin pharmaceutical rose by the limit**
On May 17, some listed pharmaceutical companies continued to rise. As of the closing of the day, Fangsheng pharmaceutical closed up 6.86%, step pharmaceutical closed up 0.13% and Bio Valley closed up 3.26%.
The concept of stephanine immediately attracted the attention of the capital market. Investors have gone to the interactive platform to ask listed companies whether they are involved in the stephanine business As of May 17, on the interactive trading platform of Shenzhen Stock Exchange, the number of investor questions and answers with stephanine as the keyword has reached 240
From the reply content, some listed companies responded to the production and sales of stephanine. On May 16, Rhine Bio said on the interactive platform that at present, the company's products and processes do not cover the extraction of stephanine, but the company has the extraction technology reserve of similar products.
For example, there will be a large demand in the stephanine market in the future. With many years of experience in plant extraction and the technical accumulation of similar products, the company is confident to carry out new technology research and development quickly and respond to the market demand in time.
However, generally speaking, the investor interaction platform mostly clarifies the announcement for listed companies, saying that the company's business is not related to or contributes less to stephanine
From May 16 to 17, more than 10 listed companies, including Jilin Aodong, Fu'an pharmaceutical, Zhendong pharmaceutical, Longjin pharmaceutical, Shuangcheng pharmaceutical, Chengzhi Co., Ltd., Rundu Co., Ltd. and Cylon pharmaceutical, said on the investor interaction platform that the company's main business did not involve stephanine for the time being.
